<DOC>
	<DOCNO>NCT00460421</DOCNO>
	<brief_summary>20010133 open-label , dose escalation study pediatric patient acute leukemias receive myelotoxic therapy ( high dose etoposide , cyclophosphamide total body irradiation [ TBI ] ) follow hematopoietic stem cell transplant ( HSCT ) . The study evaluate safety pharmacokinetics palifermin pediatric patient . Three dos ( 40 μg/kg/day , 60 μg/kg/day , 80 μg/kg/day ) evaluate age group ( 1 2 , 3 11 , 12 16 year , respectively ) use conventional dose escalation design . Palifermin administer 3 consecutive day ( Day -10 Day -8 , respectively ) start condition regimen 3 consecutive day ( Day 0 Day +2 ) follow HSCT . Patients enrol simultaneously age group identify safe , well tolerate , efficacious dose age group . Patients also follow secondary malignancy , progression-free survival ( PFS ) overall survival ( OS )</brief_summary>
	<brief_title>A Phase 1 Dose-escalation Study Evaluate Safety Pharmacokinetics ( PK ) Palifermin Subjects With Acute Leukemias Undergoing HSCT</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<criteria>1 . Acute lymphoblastic leukemia ( ALL ) acute myeloid leukemia ( AML ) require HSCT 2 . Age ≥ 1 ≤ 16 year screen 3 . Lansky performance status &gt; 60 % 4 . Candidate allogeneic HSCT protocol : Adequate kidney function : Serum creatinine : ≤ 1.5 mg/dL creatinine clearance radioisotope glomerular filtration rate ( GFR ) ≥ 60 mL/min/1.73m2 Adequate liver function : Serum total bilirubin : ≤ 2.0 mg/dl ; aspartate transaminase ( AST ) /alanine aminotransferase ( ALT ) ≤ 4.0 x institutional upper limit normal ( IULN ) ; Albumin ≥ 2 g/dL Adequate cardiac function : shortening fraction &gt; 29 % documented echocardiogram , ejection fraction ≥ 50 % document multigated acquisition scan ( MUGA ) . Adequate pulmonary function document correct lung diffusion capacity test ( DLCO ) &gt; 50 % oxygen saturation ≥ 92 % room air unable perform pulmonary function test Negative human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , human T cell lymphotropic virus ( HTLV ) 5 . Identification HLAcompatible donor per institutional standard 6 . Assent minor ( child capable give assent ) per Department Health Human Services ( DHHS ) guideline list 21CFR 50.55 local Institutional Review Board ( IRB ) standard . 7 . Serum amylase lipase : ≤ 1.2 x IULN 8 . Negative serum/urine pregnancy test female childbearing potential within 4 day administration first palifermin dose 9 . Agreement male female reproductive potential use effective mean contraception 30 day prior enrollment Day +30 ( end treatment ) 1 . Prior treatment palifermin keratinocyte growth factor 2 . Received investigational product device , exception investigational stem cell separator , another clinical trial within 30 day enrollment . 3 . Known life threaten infection respond well treatment 4 . Past history venoocclusive disease liver 5 . Known sensitivity Escherichia coliderived product grade 3 4 allergy Lasparaginase [ grade 1 2 allergy Lasparaginase allow ] . 6 . Receiving glutamine medication reduce incidence oral mucositis ( OM ) within 30 day enrollment 7 . Previous concurrent malignancy entry diagnostic criterion and/or solid organ transplantation and/or treatment congenital immunodeficiency 8 . History pancreatitis 9 . Breastfeeding ( give )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Oral Mucositis</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Palifermin</keyword>
	<keyword>Kepivance</keyword>
</DOC>